Bladder Cancer Clinical Trials

Treatment with UGN-102 has shown promise as a non-surgical alternative when compared with a surgical approach for certain patients with bladder cancer.

Here are some of the top stories from the recent Gastrointestinal Cancers Symposium as well as the Genitourinary Cancers Symposium.

Adjuvant Opdivo showed a significant improvement in overall survival and disease-free survival for patients with high-risk muscle-invasive urothelial cancer after radical resection.

The Food and Drug Administration recently approved treatment for some patients with neuroblastoma, kidney cancer and bladder cancer. Elsewhere, a cancer vaccine made headlines for the treatment of patients with melanoma.

Treatment with UGN-102 in patients with recurrent low-grade intermediate-risk non-muscle-invasive bladder cancer demonstrated beneficial responses.

The accelerated approval of Trodelvy for patients with metastatic urothelial cancer has been voluntarily withdrawn.